Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ryan, Robin
AflacST1502, NCT02574728: Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors	Recruiting	2	60	US	Sirolimus, Rapamune, rapamycin, Celecoxib, Etoposide, Etopophos, Toposar, Cyclophosphamide, Cytoxan	Emory University, Cannonball Kids' Cancer Foundation, Hyundai Hope On Wheels	Cancer	02/25	02/25
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL	Active, not recruiting	2	121	Europe, Canada, US	CTL019	Novartis Pharmaceuticals, Children's Oncology Group	B-Cell Acute Lymphoblastic Leukemia	10/27	10/27
NCT03507491: Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors	Completed	1	24	US	Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane	Emory University, Celgene Corporation	Cancer	02/24	02/24
Phifer, Eileen
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL	Active, not recruiting	2	121	Europe, Canada, US	CTL019	Novartis Pharmaceuticals, Children's Oncology Group	B-Cell Acute Lymphoblastic Leukemia	10/27	10/27